GVHD
Clinical trials for GVHD explained in plain language.
Never miss a new study
Get alerted when new GVHD trials appear
Sign up with your email to follow new studies for GVHD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to stop transplant complication
Disease control CompletedThis study tested a new approach to prevent graft-versus-host disease (GVHD), a serious complication that can occur after a stem cell transplant. Researchers combined the drug pacritinib with two standard immune-suppressing medicines (sirolimus and tacrolimus) in 40 adults receiv…
Matched conditions: GVHD
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New drug combo may reduce severe transplant complications in blood cancer patients
Disease control CompletedThis study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…
Matched conditions: GVHD
Phase: PHASE2 • Sponsor: Dimitrios Tzachanis, MD PhD • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug combo shows promise in preventing transplant complications
Disease control CompletedThis early-phase study tested whether adding a drug called BMS-986004 (which blocks CD40-L) to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD is a s…
Matched conditions: GVHD
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Blood test may predict deadly transplant reaction
Knowledge-focused CompletedThis study looked at whether a specific cell count in the blood can predict acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant for blood cancer. Researchers measured endothelial cells in blood samples from 50 patients before transplant. The goal was…
Matched conditions: GVHD
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated May 26, 2026 05:56 UTC
-
Scientists engineer 'smarter' IL-2 to tame overactive immune systems
Knowledge-focused CompletedThis study tested specially engineered versions of a natural immune protein (IL-2) in blood samples from 67 people with autoimmune or inflammatory diseases like lupus, multiple sclerosis, and rheumatoid arthritis. The goal was to see if these modified proteins could selectively a…
Matched conditions: GVHD
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:18 UTC